Stocksigma LogoStocksigma Logo

Shilpa Medicare Receives SEC Approval for Novel Injectable OERIS

Shilpa Medicare received final approval on 11th Sep'26 from the Subject Expert Committee under CDSCO for marketing authorization of OERIS (Ondansetron

Shilpa Medicare Receives SEC Approval for Novel Injectable OERIS

Shilpa Medicare Ltd 路 Press Release 路 11 Sept 2026, 6:55 pm

Shilpa Medicare Receives SEC Approval for Novel Injectable OERIS Shilpa Medicare received final approval on 11th Sep'26 from the Subject Expert Committee under CDSCO for marketing authorization of OERIS (Ondansetron Extended-Release Injection, 100 mg/mL). Designed as the world's first extended-release ondansetron injection, OERIS provides up to 120 hours of antiemetic protection from a single dose for chemotherapy-induced nausea and vomiting. Backed by successful Phase III trials, the product holds Indian patent protection until 2039. The company plans a commercial rollout across India upon receiving final marketing authorization from CDSCO.

Original exchange filing (PDF)

More announcements from Shilpa Medicare Ltd

All Shilpa Medicare Ltd announcements